Eloxx Pharmaceuticals initiates Phase 2 clinical trial for ELX-02
Category: #health  By Mateen Dalal  Date: 2019-08-07
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Eloxx Pharmaceuticals initiates Phase 2 clinical trial for ELX-02

Six patients will be registered for the trial and will be treated with ELX-02 for four weeks with three rising dose levels.

Eloxx Pharmaceuticals, Inc., an American biopharmaceutical company focused on the discovery and development of novel therapeutics to treat inherited retinal disorders, cystinosis, cystic fibrosis and other diseases caused by nonsense mutations preventing production of functional proteins, has recently shared that it has started with the Phase 2 clinical trial for ELX-02 (study 003) in cystinosis in Canada.

According to reliable sources, study 003 is a single arm, open label study developed to assess the tolerability, safety, pharmacokinetics (PK) and PD (pharmacodynamics) of subcutaneous (SC) ELX-02 in people with nephropathic cystinosis with minimum 1 nonsense mutation in the cystinosin gene. 

Speaking on the announcement, Dr. Paul Goodyer, Professor of Pediatrics, McGill University, said that the company is excited to initiate ELX-02 to cystinosis patients, a new potential treatment option which has recorded encouraging results in animal and cellular models with dose-dependent reductions in white blood cell cystine levels, a biomarker used to predict clinical benefit and to monitor cysteamine therapy.

He said that there is a high unmet medical need in cystinosis which is identified in infancy, and the emergence of new therapeutic options that could alter the course of this disease could drastically improve the lives of patients.

According to Dr. Greg Williams, PhD, COO, Eloxx Pharmaceuticals, their firm is delighted to initiate the Phase 2 clinical trial for ELX-02 in cystinosis patients with at least one nonsense mutation in Canada and are grateful for the non-dilutive funding and support it has received for this clinical trial from Genome Canada and Genome Quebec.

He added that the company is looking forward to reporting top line data from this trial in early Q4 2019. The firm believes the initial results from their renal impairment study, as well as the results till date offer support both for continuing their clinical development programs and assessing the aptness of their ERSG library for advancement in additional renal disorders, involving cystinuria and autosomal dominant polycystic kidney disease, cites Williams.

Source Credit: https://investors.eloxxpharma.com/news-releases/news-release-details/eloxx-pharmaceuticals-announces-initiation-phase-2-clinical

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Facebook to allow staff to permanently work from home post the pandemic

Facebook to allow staff to permanently work from home post the pandemic

By Mateen Dalal

Social media giant Facebook Inc. is reportedly planning to allow staff to continue working from home even after the Coronavirus pandemic ends. Eligible staff will be able to apply for permanent work from home, although subject to their relevant manag...

Lo! Foods bags USD 1 million in pre-series A funding, eyes expansion

Lo! Foods bags USD 1 million in pre-series A funding, eyes expansion

By Mateen Dalal

Lo! Foods, a Bengaluru-based consumer goods startup has reportedly secured USD 1 million during its pre-series A funding round, which was led by Chona Family Office, the former promoters of the renowned Hamvor Ice Cream. Other investors that partici...

U.S. DOJ to intensify review of American Airlines-JetBlue partnership

U.S. DOJ to intensify review of American Airlines-JetBlue partnership

By Mateen Dalal

American Airlines and JetBlue had announced their partnership in July last year. According to the Justice Department, the deal may cause inflated fares at major traffic hubs. The United States Department of Justice (DOJ) has reportedly stepped ...